Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPC + apatinib + camrelizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of the TPC chemotherapy regimen (nab-paclitaxel, cisplatin, and capecitabine) together with apatinib (a small molecule tyrosine kinase inhibitor targeting VEGFR-2) and camrelizumab (a humanized monoclonal antibody targeting PD-1). The combination is being studied for its efficacy and safety in high-risk regionally advanced nasopharyngeal carcinoma. Nab-paclitaxel disrupts microtubule function; cisplatin forms DNA crosslinks leading to apoptosis; capecitabine is a prodrug of 5-fluorouracil inhibiting DNA synthesis. Apatinib inhibits angiogenesis by blocking VEGFR-2 signaling. Camrelizumab blocks the PD-1 immune checkpoint pathway, enhancing anti-tumor immune responses[2][4][3][6].
- Brand names
- AiTanAiKeWeiAbraxaneXeloda
- Other names
- TPC regimen plus apatinib and camrelizumabnab-paclitaxel + cisplatin + capecitabine + apatinib + camrelizumab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on TPC + apatinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPC + apatinib + camrelizumab.